


Cancer Molecular Pathology and Therapeutic Targets Group

Publications: 12

Impact Factor: 31.⁹¹⁹

Q1: 3



Research Activity

Publications

- Alonso-Rodríguez E, González-Martín-Moro J, Cebrián-Carretero JL, del Castillo JL, Pozo-Kreilinger JJ, Ruiz-Bravo E, García-Arranz M, Hernández-Goday J, Burgueno M. Bisphosphonate-related osteonecrosis. Application of adipose-derived stem cells in an experimental murine model. *Med Oral Patol Oral*. 2019; 24(4): E529-36. Article. IF: 1.596; Q3
- Costales-Carrera A, Fernández-Barral A, Bustamante-Madrid P, Guerra L, Cantero R, Barbachano

A, Munoz A. Plocabulin displays strong cytotoxic activity in a personalized colon cancer patient-derived 3D organoid assay. *Mar Drugs*. 2019; 17(11): 648. Article. IF: 4.073; Q2

- Cruz Castellanos P, Ruiz-Giménez L, Romera P, Hardisson D, Amengual M. Hospital tumor registry in the Hospital La Paz [Spain]. *Rev Esp Patol*. 2019; 52(2): 72-5. Article. Not Indexed
- García Tirado A, Asencio Durán M, Berjón A, Ruiz Bravo-Burguillo E, Peralta Calvo J. Clinical and histopathological features of choroidal melanoma-

related enucleated eyes in a Spanish tertiary hospital. *Arch Soc Esp Oftalmol*. 2019; 94(5): 225-31. Article. Not Indexed

- González-Benítez C, Salas P, Grabowski JP, Hernández A, de Santiago J, Zapardiel I. Lack of survival benefit of para-aortic lymphadenectomy in advanced cervical cancer. *Gynecol Obstet Inves*. 2019; 84(4): 407-11. Article. IF: 1.281; Q4
- Migueláñez-Medrán BD, Pozo-Kreilinger JJ, Cebrián-Carretero JL, Martínez-García MA, López-Sánchez AF. Oral squamous cell carcinoma of

tongue: Histological risk assessment. A pilot study. *Med Oral Patol Oral*. 2019; 24(5): E603-9. Article. IF: 1.596; Q3

- Minig L, de Santiago J, Domingo S, Gil-Moreno A, Martínez S, Rodríguez-Garzotto A, Chiva L. Optimization of surgical treatment of advanced ovarian cancer: a Spanish expert perspective. *Clin Transl Oncol*. 2019; 21(5): 656-64. Article. IF: 2.737; Q3
- Osorio-Silla I, Valdazo AG, Méndez JIS, York E, Díaz-Almirón M, Ramírez JG, Fidalgo SR, Oliver JM, Álvarez CM, Hardisson D, Miguel MD, Lobo F, Domínguez



JD. Is it always necessary to perform an axillary lymph node dissection after neoadjuvant chemotherapy for breast cancer? *Ann Roy Coll Surg.* 2019; 101(3): 186-92. Article. IF: 1.22; Q4

- Pastrán LG, Ruz-Caracuel I, González RS. Giant primary neuroendocrine neoplasms of the liver: Report of 2 cases with molecular characterization. *Int J Surg Pathol.* 2019; 27(8): 893-9. Article. IF: 0.872; Q4
- Povedano E, Montiel VRV, Valverde A, Navarro-Villoslada F, Yáñez-Sedeno P, Pedrero M, Montero-Calle A, Barderas R, Peláez-García A, Mendiola M, Hardisson D, Feliú J, Camps J, Rodríguez-Tomás E, Joven J, Arenas M, Campuzano S, Pingarrón JM. Versatile electroanalytical bioplatforms for simultaneous determination of cancer-related DNA 5-methyl- and 5-hydroxymethyl-cytosines at global and gene-specific levels in human serum and tissues. *ACS Sens.* 2019; 4(1): 227-34. Article. IF: 7.333; D1
- Ruz-Caracuel I, Ramón-Patiño JL, López-Janeiro A, Yébenes L, Berjón A, Hernández A, Gallego A, Heredia-Soto V, Mendiola M, Redondo A, Peláez-García A, Hardisson D. Myoinvasive pattern as a prognostic marker in low-grade, early-stage endometrioid endometrial carcinoma. *Cancers [Basel].* 2019; 11(12): 1845. Article. IF: 6.126; Q1
- Vela M, Bueno D, González-Navarro P, Brito A, Fernández L, Escudero A, Valentín J, Mestre-Durán C,

Arranz-Álvarez M, de Diego RP, Mendiola M, Pozo-Kreilinger JJ, Pérez-Martínez A. Anti-CXCR4 antibody combined with activated and expanded natural killer cells for sarcoma immunotherapy. *Front Immunol.* 2019; 10: 1814. Article. IF: 5.085; Q1

Research projects

Guerra Pastrán L. Desarrollo de tareas de revisión patológica nacional del ensayo clínico paediatric hepatic international tumour trial. Fundacion para la Investigación Biomedica de Córdoba. 2019-Ongoing.

Managment centre: FIBHULP

Hardisson Hernández D. Actividades y trabajos realizados por el grupo de investigación de oncología traslacional del IdiPAZ. Universidad Europea de Madrid S.L. 2017-Ongoing.

Managment centre: FIBHULP

Hardisson Hernández D. Aplicabilidad de la proteogenómica en la progresión del carcinoma endometriode de endometrio diagnostica-do en estadios iniciales [PI17/01723]. ISCIII. 2018-2020.

Managment centre: FIBHULP

Hardisson Hernández D. Riesgo de recaída en pacientes con carcinoma de mama primario Her2 negativo y receptores estrogénicos positivos: estudio comparativo de dos perfiles de expresión génica (MammaPrint® y EndoPredict®). Fundación Sociedad Española de Anatomía Patológica. 2019-Ongoing.

Managment centre: FIBHULP

Mendiola Sabio M. Exploration of 2 and 3 models of angiosarcoma and their farcological screening. Grupo Español de Investigacion en Sarcomas. 2019-Ongoing.

Managment centre: FIBHULP

Mendiola Sabio M. Realización de técnicas de detección de expresión proteica el IGTP. Construcción de matrices tisulares y tinciones con anticuerpos específicos. Fundacio Institut Dínvestigació en Ciéncies de la Salut Germans Trias i Pujol. 2015-Ongoing.

Managment centre: FIBHULP

Clinical trials

Mendiola Sabio M. Incidence of somatic and germline BRCA mutations in a spanish large

clinic-based cohort of patients with non-mucinous epithelial ovarian cancer with cross-laboratory validation of somatic technique (Borneo). Type: ESTUDIOS, phase NO-EPA.

HULP code: PI-3544.

Sponsored's protocol code: GEICO 1703.

Sponsored by: Grupo Español de Investigación Cáncer de Ovario (GEICO).

Signed date: 24/07/2019

Patents and trademarks

Redondo Sánchez A, Hardisson Hernández D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's clinical response to an anticancer treatment. P200930400; 2009 July 01.

Redondo Sánchez A, Hardisson Hernández D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's pathological response to an anticancer treatment. P200930438; 2009 July 10.